Eli Lilly CEO David Ricks said that since the launch of the new Medicare coverage in July, about 700,000 newly eligible and existing senior patients have begun using GLP-1 drugs, about 70% of whom are using Eli Lilly products. These are the company’s staged figures. The coverage scope, the statistical period, and the definition of “new patients” still need to be confirmed, but the direction is clear: lower payment thresholds are pulling more people into this market.

The transmission logic is not complicated. Medicare coverage means reduced out-of-pocket pressure for elderly patients, which may increase prescribing willingness and refill rates. As one of the main suppliers, Eli Lilly would directly benefit from the volume ramp-up. However, this time the provided market data is empty, so I can’t use that day’s stock price, trading volume, or sector performance to verify whether the “news has already been priced in.” This needs to be stated plainly.

What’s worth watching is the structure rather than the overall volume. If 70% market share continues, it suggests Eli Lilly’s advantage in physician mindshare and supply capacity in the senior channel; however, competitors are also expanding capacity, and oral formulations and next-generation weight-loss drugs are being rolled out, so the share is not locked in. Also, it remains to be confirmed how many of the newly treated patients are truly long-term users rather than just trying it in the short term.

Next, I will prioritize researching three things: the specific reimbursement criteria and copay amounts under Medicare coverage; the month-to-month changes in Eli Lilly’s and its competitors’ capacity and prescription shares; and whether the GLP-1 revenue growth rate in the company’s subsequent earnings reports matches the narrative of these 700,000 people. If later data show that new prescriptions quickly fall off, or if competitors’ market share rises noticeably, then this assessment that “Medicare expansion unlocked incremental demand” would need to be revised.

Risk disclaimer: This article is for informational interpretation only and does not constitute investment advice.